Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

Exclusion Criteria

• •Pregnant or lactating women and male partners of women who are pregnant or lactating
• •Uncontrolled treated or untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg)
• •QTcF \> 450 msec for males and \> 470 msec for females at Screening or Day -1
• •Donation or loss of blood over 350 mL within 60 days prior to screening
• •Any evidence of progressive liver disease within the last 4 weeks for subjects with hepatic impairment